- Supported exchanges /
- TWO /
- 1799.TWO
Easywell Biomedicals Inc. (1799 TWO) stock market data APIs
Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine, as well as provides medical devices. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Easywell Biomedicals Inc. Financial Data Overview
| 107 | |
| 105 | |
| - | |
| 110 | |
| 100.5 | |
| 27.547-233 | |
| 13 040 M | |
| 122 M | |
| 361 M | |
| 0.527 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Easywell Biomedicals Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 361 M
- EBITDA -114 084 000
- Earnings Per Share -1.2
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Easywell Biomedicals Inc. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Easywell Biomedicals Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
